FindTrial
Sign In

A comparative study on effectiveness, safety, and treatment persistence of different biologics in patients with biologic-naïve Crohn's disease: a multicenter, retrospective, real-world study

A comparative study on effectiveness, safety, and treatment persistence of different biologics in patients with biologic-naïve Crohn's disease: a multicenter, retrospective, real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300079034
Enrollment
Unknown
Registered
2023-12-25
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Infliximab Group:No intervention
Vedolizumab Group:No intervention
Ustekinumab Group:No intervention

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Diagnosis of Crohn's disease. 2.No previous use of biologics or small molecule agents. 3.The subject plans to accept infliximab, vedolizumab or ustekinumab to treat Crohn's disease. 4.Aged = 18 years when receiving biologics, inclusive. 5.Following = 1 year after treatment.

Exclusion criteria

Exclusion criteria: 1.Use of other biologics or small molecule agents in combination with treatment. 2.Incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Effectiveness;—

Secondary

MeasureTime frame
Safety;Treatment persistence;—

Countries

China

Contacts

Public ContactQian Cao

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

caoq@zju.edu.cn+86 135 8870 6896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026